Innovation and excellence in science and health
AstraZeneca (and their global biologics research and development arm MedImmune) are establishing a new Global R&D Centre and Corporate Headquarters in Cambridge on the Cambridge Biomedical Campus, the future home to approximately 2,000 employees. The site on the Cambridge Biomedical Campus will become their largest centre for oncology research worldwide. Beyond cancer research, their R&D focuses on cardiovascular and metabolic diseases, respiratory, inflammation and autoimmune diseases and conditions of the central nervous system. The site will bring together their small molecule and biologics R&D, opening up opportunities to exploit the promise of small and large molecule combinations. Additionally, they will have medicinal chemistry, high-throughput screening and cellular and molecular biology, as well as clinical development and pre-clinical research capabilities located on the site.
View from Robinson Way-North
Key features of the site include:
- Science at the heart – the high technology labs on the site will be separated from other work spaces by glass walls to promote ‘visible science’, ensuring scientific innovation is the primary focus for all staff, both in R&D and other functions
- Fostering collaboration –the site will feature a number of open spaces and thoroughfares to encourage collaboration not only within AstraZeneca, but also with the wider scientific community within the CBC and beyond.
- Reflecting the character of the City – the unique characteristics of Cambridge’s historic centre have influenced the shape of the buildings. The site will be low rise and will include a central courtyard reflecting the colleges of Cambridge University.
- An environmental build –AstraZeneca is seeking Building Research Establishment Environmental Assessment Methodology (BREEAM) Excellent status for the site, which will feature labs that represent best practice in low energy design and the largest ground source heat pump in Europe. “Green Roofs” will also be installed across the majority of the site.
Recent collaborations AstraZeneca has entered into in Cambridge include:
- In May 2014 AstraZeneca announced its intention to collaborate with the Medical Research Council (MRC) Laboratory of Molecular Biology to fund a range of pre-clinical research projects, aimed at better understanding the biology of disease.
- In March 2014 AstraZeneca and the MRC announced the creation of the AstraZeneca MRC UK Centre for Lead Discovery, which will sit within the new AstraZeneca site at the Cambridge Biomedical Campus and see AstraZeneca and MRC-supported researchers working side-by-side.
- In February 2014 AstraZeneca entered into a collaboration with the Cancer Research UK Cambridge Institute, to locate up to 60 of the Company’s scientists in the Institute’s state of the art labs on the CBC over the next three years. The first of AstraZeneca’s scientists have already moved into the Cambridge Institute labs.